How should sacubitril/valsartan (Entresto) be initiated and titrated in a hemodynamically stable chronic heart‑failure patient already on optimal background therapy?

Initiating and Titrating Entresto (Sacubitril/Valsartan) in Hemodynamically Stable CHF

Start sacubitril/valsartan at 49/51 mg twice daily in hemodynamically stable heart failure patients already on optimal therapy, then double the dose every 2-4 weeks to reach the target of 97/103 mg twice daily, as tolerated. 1, 2

Pre-Initiation Requirements

Before starting sacubitril/valsartan, ensure:

• 36-hour washout from ACE inhibitors (mandatory to prevent angioedema) 1, 2
• No washout needed when switching from ARBs 1
• Patient is hemodynamically stable without need for IV inotropes 1
• Systolic blood pressure ≥100 mmHg (though lower BP should not automatically exclude therapy) 1, 3
• Check baseline renal function (eGFR), potassium, and blood pressure 1

Standard Dosing Algorithm

For Patients on High-Dose ACEi/ARB:

Starting dose: 49/51 mg twice daily 1, 2

• High-dose defined as: enalapril ≥10 mg daily or valsartan ≥160 mg daily
• Titrate to 97/103 mg twice daily after 2-4 weeks 1, 2

For Patients on Low/Medium-Dose ACEi/ARB or ACEi/ARB-Naive:

Starting dose: 24/26 mg twice daily 1, 2

• Includes patients not previously on these medications (de novo initiation is now recommended) 1
• Titrate to 49/51 mg after 2-4 weeks
• Then titrate to 97/103 mg after another 2-4 weeks 2

Special Populations Requiring Lower Starting Dose (24/26 mg):

• Severe renal impairment (eGFR <30 mL/min/1.73 m²) 1
• Moderate hepatic impairment (Child-Pugh B) 1
• Age ≥75 years 1

Titration Strategy

The 2021 ACC Expert Consensus strongly supports gradual titration over 3-6 weeks rather than rapid titration, as this maximizes achievement of target doses, particularly in patients on lower baseline ACEi/ARB doses. 1 The TITRATION study demonstrated that gradual uptitration was better tolerated, especially in patients with systolic BP 100-110 mmHg 4.

Monitoring Schedule:

• Check BP, renal function, and electrolytes 1-2 weeks after each dose increment 1
• Recheck at 3 months, then every 6 months 1
• Monitor for symptoms of hypotension, hyperkalemia, and worsening renal function 1

Managing Common Barriers

Hypotension:

• Asymptomatic low BP should NOT prevent initiation or uptitration 3
• If symptomatic hypotension occurs with systolic BP >90 mmHg: reduce other vasodilators first, consider modest reduction in loop diuretics if patient is not congested 1
• Only reduce sacubitril/valsartan if BP <80 mmHg or symptomatic despite other adjustments 3
• The TITRATION study showed that >70% of patients with baseline systolic BP 100-110 mmHg achieved target dose with gradual titration 4

Renal Dysfunction:

• Stop if creatinine doubles or eGFR drops significantly 1
• Avoid potassium-sparing diuretics during initiation 1
• If serum K+ ≥5.5 mmol/L, hold dose and recheck 1

Volume Status:

• Ensure patient is not volume-depleted before initiation (reduces hypotension risk) 1
• Consider empiric modest reduction in loop diuretics in non-congested patients to mitigate hypotensive effects 1

De Novo Initiation (Direct-to-ARNI Approach)

Recent evidence strongly supports initiating sacubitril/valsartan directly without prior ACEi/ARB exposure. 1 The PROVE-HF and PIONEER-HF studies demonstrated that de novo initiation is safe and effective, with no unexpected adverse effects compared to patients already on ACEi/ARB 1. This approach avoids delays in achieving optimal therapy and has shown superior early clinical outcomes 1.

Key Contraindications

• History of angioedema (with or without ACEi/ARB) 1
• Within 36 hours of ACEi use 1, 2
• Pregnancy 1
• Severe hepatic impairment (Child-Pugh C) 1
• Concomitant aliskiren in diabetic patients 1

Critical Pitfalls to Avoid

1. Do NOT require aldosterone antagonist use before initiating sacubitril/valsartan - there is no evidence this is mandatory 1
2. Do NOT withhold therapy solely based on low BP readings - focus on symptoms and organ perfusion 3
3. Do NOT skip the 36-hour ACEi washout - this is mandatory to prevent angioedema 1, 2
4. Do NOT abandon uptitration attempts prematurely - gradual titration over 6 weeks achieves target doses in most patients 4

Real-World Considerations

Real-world data shows only 27% of patients achieve target dose within 6 months in clinical practice 5, primarily due to slower uptitration than in trials, not true intolerance. Close follow-up and serial assessments are essential to overcome clinical inertia and maximize dose achievement. 1 The 2022 AHA/ACC/HFSA guidelines emphasize that titration to target doses shown effective in trials is a Class I recommendation to reduce cardiovascular mortality and HF hospitalizations 6.